Alisa Selimovic

Alisa Selimovic is an accomplished professional in the life sciences and biomedical engineering sectors, currently serving as Executive Chair at Resseptor Therapeutics and Senior Investment Manager at IP Group plc since April 2023 and June 2018, respectively. With experience as a Board Observer at both RAGE Biotech and Jetra Therapeutics, Alisa has demonstrated expertise in corporate development during tenure at Circassia, focusing on M&A and in-licensing opportunities. Previous roles include Senior Business Analyst and Business Analyst at PharmaVentures, Research Assistant at Oxford University, and Projects Engineer at SA Pathology. Alisa holds a Doctor of Philosophy from the University of Oxford and a Bachelor of Engineering from Flinders University, complemented by a Company Directors Course from the Australian Institute of Company Directors.